{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of LFCN Block Addition to PENG Block in Hip Fracture Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "60 patients aged 18-75 undergoing hip fracture surgery were randomised into three groups"
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at Zonguldak B\u00fclent Ecevit University Hospital, T\u00fcrkiye, 60 patients aged 18-75 undergoing hip fracture surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "The PENG group received 20 mL of 0.25% bupivacaine, while the PENG + LFCN group received an additional 5 mL LFCN block"
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial evaluated the effect of adding a lateral femoral cutaneous nerve (LFCN) block to a pericapsular nerve group (PENG) block on postoperative opioid consumption and pain scores in hip fracture surgery under spinal anesthesia."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was postoperative opioid consumption within 24 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-assisted with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "60 patients aged 18-75 undergoing hip fracture surgery were randomised into three groups"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "60 patients were analysed (20 per group) using a per-protocol approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Postoperative opioid consumption was significantly lower in the PENG (8.10 \u00b1 6.72 mg) and PENG + LFCN (8.40 \u00b1 4.38 mg) groups compared to CONTROL (15.30 \u00b1 5.59 mg, P < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT06226675."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}